| Rus |  |
Eng |  |
Doctor Honoris Causa award ceremony took place at Paul Sabatier University of Toulouse III, France on October 08, 2014. This award, named Doctor Honoris Causa, is the highest of the French University since the 17th century, that honors the excellence of eminent scientists and is giving for outstanding achievements in science and education.
Four famous scientists received the honor that time from the President of Paul Sabatier University, Prof. Bertrand Monthubert : Dr. Yury GOGOTSI (Drexel University, USA), Dr Jaime BOSCH (University of Barcelona, Spain), prof. M. Guy-Bernard CADIERE (Free University of Brussels, Belgium), prof. Naruya SAITOU (National Institute of Genetics , Japan).
Yury GOGOTSI – Distinguished University and Trustee Chair Professor, Director of A.J. Drexel Nanotechnology Institute, USA.
He also holds appointments in the Departments of Chemistry and Mechanical Engineering and Mechanics at Drexel University and serves as Director of the A.J. Drexel Nanotechnology Institute. He is a specialist in the synthesis and characterization of materials, especially carbon materials. He also reported carbon transformation of diamond to graphite under compression, opening the way for the possibility of diamond machining (Nature 1999).
Jaime BOSCH - Dr Jaime Bosch is currently Professor of Medicine and Chief of Hepatology Section at the IMD, Hospital Clinic, University of Barcelona, Spain. Since 2000, Dr Bosch has been the Coordinator of the Department of Liver, Gastroenterology and Metabolism at the Institut d’Investigació Biomèdica August Pi i Sunyer, Barcelona, and Research Coordinator of the Institut de Mlalties Digestives, Hospital Clínic, Barcelona. He is also the Coordinator of the National Network of Research in Hepatology and Gastroenterology. His particular research interests are the pathophysiology and treatment of portal hypertension. Dr Bosch is a fellow of the ACD, Asociación Española para el Estudio del Hígado, European Association for the Study of the Liver, American Association for the Study of Liver Diseases and IASL.
M. Guy-Bernard CADIERE - Professor of Free University of Brussels, Belgium, Chief of G.I. surgery, Saint Pierre University Hospital, Brussels, Belgium. Professor Guy-Bernard Cadiere is Doctor of Medicine and also holds a PhD in science. He is one of the world leaders in the field of laparoscopic surgery. He developed especially obesity surgery and robotic surgery. He was the first to operate with the Da Vinci robot, a patient with gastroesophageal reflux. The Americans asked him to perform for the FDA (Food and Drug Administration) the first intervention with a ring gastroplasty for obesity.
Naruya SAITOU - Professor, Division of Population Genetic, National Institute of Genetics , Mishima, Japan. Professor Naruya Saitou is a Doctor of Science (Ph. D), specializing in phylogenetic reconstruction and the evolution of genes. He is the inventor of the method of reconstruction of phylogenetic trees. He created new methods of phylogenetic reconstructions based on multidimensional networks. He was closely involved in the study of the evolution of genes involved in the control of embryonic development and blood group genes.Professor Saitou Naruya received honorary awards such as 'Research Promotion Award, Genetics Society of Japan' and 'The 12th Academic Award, Kihara Memorial Foundation'.
Source: http://www.univ-tlse3.fr/1412754167772/1/fiche___actualite/&RH=rub03
MXenes potential applications include sensors, wound healing materials, and drug delivery systems. A recent study explored how different synthesis methods affect the safety and performance of MXenes. By comparing etching conditions and intercalation strategies, researchers discovered that fine-tuning the surface chemistry of MXenes plays a crucial role in improving biocompatibility. These results provide practical guidelines for developing safer MXenes and bring the field one step closer to real biomedical applications.
Exellent news, our joint patent application with Drexel University on highly porous MAX phase precursor for MXene synthesis published. Congratulations and thanks to all team involved!
Our team was very delighted to take part in International Symposium "The MXene Frontier: Transformative Nanomaterials Shaping the Future" – the largest MXene event in Europe this year! 
Last Call! Have you submitted your abstract for IEEE NAP-2025 yet? Join us at the International Symposium on "The MXene Frontier: Transformative Nanomaterials Shaping the Future" – the largest MXene-focused conference in Europe this year! Final Submission Deadline: May 15, 2025. Don’t miss this exclusive opportunity to showcase your research and engage with world leaders in the MXene field!
We are excited to announce the publication of latest review article on MXenes in Healthcare. This comprehensive review explores the groundbreaking role of MXenes—an emerging class of 2D materials—in revolutionizing the fields of medical diagnostics and therapeutics. Read the full article here: https://doi.org/10.1039/D4NR04853A.
Congratulations and thank you to our collaborators from TU Wien and CEST for very interesting work and making it published! In this work, an upscalable electrochemical MXene synthesis is presented. Yields of up to 60% electrochemical MXene (EC-MXene) with no byproducts from a single exfoliation cycle are achieved.
Congratulations to all collaborators with this interesting joint work!
Thank you to our collaborators for the amazing joint work recently published in Graphene and 2D Nanomaterials about MXene–silk fibroin composite films aiming to develop materials with tunable electronic and thermal properties
Dr. Oleksiy Gogotsi, director of MRC and Carbon-Ukraine, innovative companies that are among the leaders on the world MXene market, visited 2024 MRS Fall Meeting & Exhibit. together with Dr. Maksym Pogorielov, Head of Advanced Biomaterials and Biophysics Laboratory, University of Latvia.
MRC and Carbon-Ukraine team visited the 3rd International MXene conference held at Drexel University on August 5-8, 2024. Conference brought together the best reserchers and leading experts on MXene field. 
Together with colleagues from the University of Latvia, MRC/Carbone Ukraine, Adam Mickiewicz University, University Clinic Essen, and others, we have developed a novel concept involving the binding of antibodies to MXenes. In our research, we utilized anti-CEACAM1 antibodies to develop targeted photo-thermal therapy for melanoma (in vitro), paving the way for future in vivo studies and clinical trials. For the first time, we demonstrate the feasibility of delivering MXenes specifically targeted to melanoma cells, enabling the effective ablation of cancer cells under near-infrared (NIR) light. This new technique opens up vast potential for the application of MXenes in cancer treatment, diagnostics, drug delivery, and many other medical purposes.